Over a median follow-up of 16 months, sotagliflozin reduced the risk of kidney-related complications by 38% and a cardiorenal composite outcome by 23%.
Sotagliflozin, a dual SGLT1 and 2 inhibitor, has been found to provide kidney and heart benefits in patients with type 2 diabetes and chronic kidney disease.
The majority of patients did not experience worsening of their diabetic retinopathy (DR) after initiating semaglutide (Ozempic) to treat their type 2 diabetes (T2D).
Recent studies have shed light on the effects of certain drugs on patients with type 2 diabetes (T2D). Semaglutide (Ozempic), a medication used to treat T2D, has been found not to worsen diabetic retinopathy (DR) in the majority of patients, contradicting previous recommendations for patients to consult with ophthalmologists prior to initiating semaglutide. The incidence of vision-threatening complications related to DR was relatively low at multiple time points after initiation of semaglutide.
In another development, Sotagliflozin, a dual SGLT1 and 2 inhibitor, has been found to provide kidney and heart benefits in patients with T2D and chronic kidney disease. An exploratory analysis of data from the SCORED trial, a phase 3, double-blind, placebo-controlled study, revealed that over a median follow-up of 16 months, sotaglutide reduced the risk of kidney-related complications by 38% and a cardiorenal composite outcome by 23%. The drug, now FDA approved under the name 'INPEFA', is used to reduce the risk of cardiovascular death and heart failure events.
However, it is important to note that while these findings are promising, they are based on specific studies and further research is needed to confirm these results and understand the long-term effects of these medications on patients with T2D and related conditions.
The findings are based on specific studies and further research is needed to confirm these results and understand the long-term effects of these medications on patients with T2D and related conditions.
The majority of patients did not experience worsening of their diabetic retinopathy (DR) after initiating semaglutide (Ozempic) to treat their type 2 diabetes (T2D).
The findings contradict recommendations for patients to consult with ophthalmologists prior to initiating semaglutide.
The incidence of vision-threatening complications related to DR was relatively low at multiple time points after initiation of semaglutide.
Sotagliflozin, a dual SGLT1 and 2 inhibitor, has been found to provide kidney and heart benefits in patients with type 2 diabetes and chronic kidney disease.
Over a median follow-up of 16 months, sotagliflozin reduced the risk of kidney-related complications by 38% and a cardiorenal composite outcome by 23%.
Sotagliflozin is now FDA approved under the name 'INPEFA' to reduce the risk of cardiovascular death and heart failure events.
The title of the article promises new insights on Hyperkalemia and safety of Kerendia for patients with Chronic Kidney Disease associated with Type 2 Diabetes, but the body of the article does not contain any information related to this.